Arden Anglican School wins SunSafe Ambassador competition
13 December 2018
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award for their engaging and inspiring presentation to their peers about how to be sun safe and help prevent melanoma.
Year 10 students Kaela (16), Oliver (16) and Kimberley (16) were nominated by their school to join other students at MIA’s one-day SunSafe Student Ambassador Program at The Poche Centre in Wollstonecraft, where they learned about melanoma and the importance of sun safety.
The program was also designed to assist students in developing their presentation skills, so they could create a personalised sun safe presentation to deliver at their school.
The students returned to their schools to deliver their own SunSafe presentation to their peers, with nine schools submitting videos of the student presentations for judging by MIA’s expert panel, including the Chair of MIA’s Education Committee Associate Professor Robyn Saw, Director of Speak Out Schools Kat Collins, and MIA CEO Matthew Browne.
The students from Arden Anglican School were announced as the winners and were today presented with their award at the final Year 10 Meeting for the year by Melanoma Institute Australia CEO Matthew Browne.
‘I thought the three Arden ambassadors were very engaging,’ said Mr. Browne.
‘Kaela, Oliver and Kimberley’s presentation would have undoubtedly convinced many of their peers to cover up and protect themselves from the sun, a critically important message particularly for teenagers.’
UV exposure leading to sunburn is the greatest risk factor for developing melanoma. One Australian dies every five hours from melanoma, which is also the most common cancer affecting 15 to 39 year old Australians.
MIA’s SunSafe Student Ambassador Program will be rolled out in six locations across east coast of Australia in late 2019. Schools interested in participating can fill out the expression of interest form here.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.